Key result
No clinical study data or findings were provided in the text, which consists only of journal editorial board information.
Why the study?
Does otamixaban alter pharmacodynamic markers of anti-coagulation in healthy male subjects?
Population
Healthy male subjects (n=80, 10 consecutive parallel groups)
Comparison
Otamixaban via escalating intravenous doses as… vs Placebo (2 subjects per group)
Design
Other
Authors
Loading...
No study data provided; leaves otamixaban PD effects in healthy subjects unaddressed.
Does otamixaban alter pharmacodynamic markers of anti-coagulation in healthy male subjects?
In a first-in-man study, the novel direct Factor Xa inhibitor otamixaban demonstrated predictable, dose-dependent pharmacodynamic effects on coagulation markers and was well tolerated.
Ozoux et al. (2005) studied this question. No clinical study data or findings were provided in the text, which consists only of journal editorial board information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: